Literature DB >> 15507225

Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm.

Junichi Miyamoto1, Minoru Tsuji, Hiroshi Takeda, Mitsuo Ohzeki, Hajime Nawa, Teruhiko Matsumiya.   

Abstract

It has been known that rodents exhibit the immobility when tested in the same environment in which they had been previously exposed to aversive stimuli. This behavior is called conditioned fear stress-induced freezing behavior, and has been used as a model of anxiety. Using this animal model, the present study tried to characterize the anxiolytic-like effects of fluvoxamine, a selective serotonin reuptake inhibitor, milnacipran, a serotonin noradrenaline reuptake inhibitor and risperidone, an atypical antipsychotic in mice. Fluvoxamine (1.25-10 mg/kg, intraperitoneally (i.p.)) and milnacipran (0.5-4 mg/kg, i.p.) each dose-dependently and significantly suppressed the conditioned fear stress-induced freezing behavior in mice, an indicator of anxiety, and milnacipran had a weaker effect than fluvoxamine. While risperidone also significantly suppressed freezing behavior at a low dose (0.01 mg/kg, i.p.), a high dose (0.04 mg/kg, i.p.) decreased spontaneous motor activity. On the contrary, sulpiride, a typical antipsychotic (2-8 mg/kg, i.p.), did not affect freezing behavior. In a combination study, the suppressive effect of a low dose of risperidone (0.01 mg/kg, i.p.) on freezing behavior was significantly antagonized by the co-administration of low/middle doses of fluvoxamine (1.25 and 2.5 mg/kg, i.p.), whereas a high dose of fluvoxamine (10 mg/kg, i.p.) was unaffected. Additionally, the co-administration of milnacipran (0.5-2 mg/kg, i.p.) also tended to inhibit the suppressive effect of risperidone (0.01 mg/kg, i.p.). These findings indicate that fluvoxamine, milnacipran and risperidone may each be clinically effective at treating anxiety disorders, but their effects may be attenuated in combination with other medications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507225     DOI: 10.1016/j.ejphar.2004.09.043

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Effects of milnacipran in animal models of anxiety and memory.

Authors:  Vânia K M Moojen; Márcio Rodrigo Martins; Adalisa Reinke; Gustavo Feier; Fabiano R Agostinho; Edson M Cechin; João Quevedo
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

2.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

3.  The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine.

Authors:  Liliana P Montezinho; Silke Miller; Niels Plath; Nanna Hovelsø Jensen; Jens-Jakob Karlsson; Louise Witten; Arne Mørk
Journal:  Psychopharmacology (Berl)       Date:  2010-07-30       Impact factor: 4.530

4.  Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice.

Authors:  Janitza L Montalvo-Ortiz; Daniel W Fisher; Guadalupe Rodríguez; Deyu Fang; John G Csernansky; Hongxin Dong
Journal:  Psychopharmacology (Berl)       Date:  2017-04-18       Impact factor: 4.530

5.  Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.

Authors:  Teruhiko Higuchi; Mike Briley
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

Review 6.  Using the conditioned fear stress (CFS) animal model to understand the neurobiological mechanisms and pharmacological treatment of anxiety.

Authors:  Xiaobai Li
Journal:  Shanghai Arch Psychiatry       Date:  2012-10

7.  Impact of Chronic Risperidone Use on Behavior and Survival of 3xTg-AD Mice Model of Alzheimer's Disease and Mice With Normal Aging.

Authors:  Virginia Torres-Lista; Secundí López-Pousa; Lydia Giménez-Llort
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

Review 8.  Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice.

Authors:  Shawniqua Williams Roberson; Mayur B Patel; Wojciech Dabrowski; E Wesley Ely; Cezary Pakulski; Katarzyna Kotfis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.